{"ticker": {"uuid": "0e6f6990-e644-4e62-a1bd-148f33309ae0", "symbol": "KTTA", "name": "Pasithea Therapeutics Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Pasithea Therapeutics (KTTA) Proxy filing Summary", "summary": "Pasithea Therapeutics (KTTA) has released a summary of its proxy filing. The annual meeting, scheduled for September 3, 2025, will cover four key proposals including director elections, auditor ratification, an amendment to the 2023 Stock Incentive Plan, and a reverse stock split", "url": "https://quartr.com/events/pasithea-therapeutics-corp-ktta-proxy-filing_F15UA5TP", "source_name": "Quartr", "published_at": "2026-07-21T22:10:29", "published_display": "21 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics (KTTA) Registration filing Summary", "summary": "Pasithea Therapeutics (KTTA) is a clinical-stage biotechnology company focused on treatments for CNS disorders, RASopathies, MAPK pathway-driven tumors, and other diseases. The company reported net losses of $13.9 million in 2024 and $16.0 million in 2023, with an accumulated def", "url": "https://quartr.com/events/pasithea-therapeutics-corp-ktta-registration-filing_F15UA5Te", "source_name": "Quartr", "published_at": "2026-07-21T21:42:00", "published_display": "21 Jul 2026 21:42", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors", "summary": "Pasithea Therapeutics Corp. announced that its Phase 1 dose-escalation study for PAS-004, a macrocyclic MEK inhibitor, has been accepted for a poster presentation at the ESMO Congress 2026 on October 23. The study focuses on the safety and pharmacokinetics of PAS-004 in patients ", "url": "https://www.quiverquant.com/news/Pasithea+Therapeutics+Announces+ESMO+2026+Poster+Presentation+of+Phase+I+PAS-004+Study+in+Advanced+Solid+Tumors", "source_name": "Quiver Quantitative", "published_at": "2026-07-21T11:39:55", "published_display": "21 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea's PAS-004 Study of Advanced Solid Tumors Gets ESMO Poster Slot", "summary": "Pasithea Therapeutics (NASDAQ: KTTA) announced that its Phase I dose-escalation study data for PAS-004, a next-generation oral macrocyclic MEK inhibitor, in MAPK pathway-driven advanced solid tumors has been accepted for a poster presentation at the ESMO Congress 2026. The presen", "url": "https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-announces-presentation-of-pas-004-data-to-3m6zebfrchwt.html", "source_name": "Stock Titan", "published_at": "2026-07-21T10:39:54", "published_display": "21 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026", "summary": "Pasithea Therapeutics announced that data from its Phase 1 dose-escalation study of PAS-004, a macrocyclic MEK inhibitor, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. The presentation will detail the safety and pharmacokinetics of PAS-004 f", "url": "https://www.globenewswire.com/news-release/2026/07/21/3330295/0/en/pasithea-therapeutics-announces-presentation-of-pas-004-data-to-european-society-for-medical-oncology-esmo-congress-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-21T07:00:00", "published_display": "21 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit", "summary": "Pasithea Therapeutics Corp. announced its management will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston. The clinical-stage biotechnology company, focused on developing PAS-004 for chronic diseases and neurofibromatosis type 1, wi", "url": "https://www.sahmcapital.com/news/content/pasithea-therapeutics-announces-participation-in-b-riley-securities-mind-muscle-vision-summit-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-09T07:12:23", "published_display": "09 Jul 2026 07:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics to present at B. Riley Mi...", "summary": "Pasithea Therapeutics, a clinical-stage biotech company developing PAS-004 for chronic diseases like neurofibromatosis type 1, will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston. This summit offers an opportunity for Pasithea to e", "url": "https://pluang.com/en/news-feed/pasithea-therapeutics-ikuti-konferensi-b-riley-securities-mind-muscle-vision", "source_name": "Pluang", "published_at": "2026-07-08T11:10:56", "published_display": "08 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea management to meet investors at B. Riley health summit in Boston", "summary": "Pasithea Therapeutics (NASDAQ: KTTA) announced its management will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston. The clinical-stage biotech, focusing on its lead drug candidate PAS-004 for chronic diseases including NF1, will eng", "url": "https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-announces-participation-in-b-riley-securities-2n9dyfpfv6y1.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:10:56", "published_display": "08 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings", "summary": "This page provides access to Pasithea Therapeutics Corp.'s financial disclosures and SEC filings, including quarterly and annual reports (10-Q and 10-K forms). Investors can use these documents to evaluate the company's financial performance and operational updates. The filings s", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTAW/documents/", "source_name": "TradingView", "published_at": "2026-07-02T00:40:00", "published_display": "02 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) \u2014 11.48% disclosed", "summary": "Coastlands Capital LP and its affiliated entities, along with Matthew D. Perry, have disclosed a beneficial ownership of 3,835,035 shares, representing an 11.48% stake in Pasithea Therapeutics (KTTA). This information comes from a Schedule 13G/A SEC filing, indicating a passive i", "url": "https://www.stocktitan.net/sec-filings/KTTA/schedule-13g-a-pasithea-therapeutics-corp-amended-passive-investment--0dbdebe49e63.html", "source_name": "Stock Titan", "published_at": "2026-07-02T00:40:00", "published_display": "02 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies.", "summary": "Pasithea Therapeutics Corp. has announced that its drug candidate, Pas-4, exhibited a favorable safety profile in clinical studies, with all observed adverse events being grade 1 or 2. This positive safety data is crucial for the drug's continued clinical development and potentia", "url": "https://www.bitget.com/amp/news/detail/12560605483584", "source_name": "Bitget", "published_at": "2026-06-30T15:09:58", "published_display": "30 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea reports positive PAS-004 Phase 1 cancer data", "summary": "Pasithea Therapeutics announced positive interim Phase 1 data for its oral MEK inhibitor, PAS-004, in patients with advanced MAPK pathway-driven solid tumors. The study revealed a favorable safety profile and instances of disease stabilization exceeding six months in heavily pret", "url": "https://grafa.com/en/news/united-states/pasithea-therapeutics-pas004-phase1-interim-results", "source_name": "grafa.com", "published_at": "2026-06-30T14:09:58", "published_display": "30 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Says Interim Phase 1 Data for PAS-004 Show Durable Clinical Activity", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pasithea-therapeutics-says-interim-phase-121951997.html", "source_name": "MT Newswires", "published_at": "2026-06-30T12:19:51+00:00", "published_display": "30 Jun 2026 12:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion", "summary": "Pasithea Therapeutics announced positive interim Phase 1 data for its drug candidate PAS-004 in advanced cancer patients, demonstrating favorable long-term safety and durable clinical activity, particularly in MEK/BRAF-pretreated individuals. The company noted that PAS-004 has be", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319538/0/en/pasithea-therapeutics-announces-positive-interim-phase-1-advanced-cancer-study-data-demonstrating-long-term-safety-and-tolerability-and-durable-clinical-activity-in-mek-braf-pretre.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:09:25", "published_display": "30 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens", "summary": "Pasithea Therapeutics announced positive interim Phase 1 data for PAS-004 in advanced cancer patients, showing favorable safety and durable disease stabilization. The oral MEK inhibitor demonstrated strong tolerability, with all adverse events being Grade 1\u20132, and pharmacokinetic", "url": "https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-announces-positive-interim-phase-1-advanced-um0jjlpge3s6.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:09:25", "published_display": "30 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pasithea Therapeutics Corp. \u2013 NASDAQ:KTTA", "summary": "This article focuses on the enterprise value to revenue forward metric for Pasithea Therapeutics Corp. (NASDAQ: KTTA). It is a brief financial snippet from TradingView, highlighting a specific valuation ratio for the company. The content appears to be a stub or a section of a lar", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:41:04", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pasithea Therapeutics Corp. \u2013 NASDAQ:KTTA", "summary": "This article displays the \"Price to book forward\" financial metric for Pasithea Therapeutics Corp. (NASDAQ: KTTA) on TradingView. It appears to be a stub or a data point within a larger financial platform, showing the value and changes for this specific financial indicator over a", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T06:42:48", "published_display": "29 Jun 2026 06:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pasithea Therapeutics Corp. \u2013 NASDAQ:KTTA", "summary": "This article provides a brief financial overview of Pasithea Therapeutics Corp. (NASDAQ: KTTA), focusing on its price-to-sales forward metric. It indicates that the market was closed at the time of publication and that there were no trades. The article is sourced from TradingView", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:10:21", "published_display": "28 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pasithea Therapeutics Corp. \u2013 BOATS:KTTAW", "summary": "The article focuses on the \"Price to sales forward\" metric for Pasithea Therapeutics Corp. (KTTAW) on the Blue Ocean Alternative Trade System (BOATS). It notes that the market was closed and there were no trades recorded for this specific financial indicator. The content is prima", "url": "https://www.tradingview.com/symbols/BOATS-KTTAW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:09:25", "published_display": "27 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pasithea Therapeutics Corp. \u2013 BOATS:KTTAW", "summary": "This article provides the enterprise value to revenue forward for Pasithea Therapeutics Corp. (KTTAW), as presented on TradingView. It notes that the market is closed with no trades. The content primarily shows navigation elements and disclaimers rather than financial data.", "url": "https://www.tradingview.com/symbols/BOATS-KTTAW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:10:33", "published_display": "26 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Corp. Actuals & Estimates (NASDAQ:KTTA)", "summary": "This article provides key financial data and analyst estimates for Pasithea Therapeutics Corp. (NASDAQ:KTTA). It covers current stock performance, historical highs and lows, future price forecasts from analysts, and upcoming earnings dates, alongside other company financials and ", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:10:33", "published_display": "26 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Corp. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of Pasithea Therapeutics Corp.'s SEC filings and other financial documents, including annual 10-K and quarterly 10-Q reports, dating back to 2021. It also lists corporate events such as conference participations. The information aims to ", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTA/documents/", "source_name": "TradingView", "published_at": "2026-06-24T05:10:02", "published_display": "24 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com", "summary": "This article announces the filing of a Form 13G for Pasithea Therapeutics Corp. on June 23. It reminds readers that trading in financial instruments and cryptocurrencies involves significant risks and that data on Investing.com may not be real-time or accurate.", "url": "https://m.za.investing.com/news/stock-market-news/form-13g-pasithea-therapeutics-corp-for-23-june-93CH-4341004?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-24T03:10:02", "published_display": "24 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Pasithea Therapeutics Corp For: 22 June By Investing.com", "summary": "This article announces the filing of a Form 4 for Pasithea Therapeutics Corp on June 22nd, as reported by Investing.com. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a co", "url": "https://ng.investing.com/news/stock-market-news/form-4-pasithea-therapeutics-corp-for-22-june-93CH-2568205", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T15:40:15", "published_display": "22 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coastlands Capital LP acquires $53,000 of Pasithea stock By Investing.com", "summary": "Coastlands Capital LP, a significant shareholder in Pasithea Therapeutics Corp., recently acquired 100,000 shares of the company's common stock for $53,000 at $0.53 per share. This transaction increases their indirect holdings to 3,835,035 shares, occurring after the stock experi", "url": "https://ng.investing.com/news/stock-market-news/coastlands-capital-lp-acquires-53000-of-pasithea-stock-93CH-2568193", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T14:39:14", "published_display": "22 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coastlands Capital LP acquires $53,000 of Pasithea stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZ1B2cG8yTjA1VDJaXzBtUmNYMjcydVE1eTdUNmFjZXZBYUtHU1NaM0xZbWt2SzVrLXVUX0pmWFA2Y3VWbHh6MC1CMEtYRVlOaS1zQkc4c0Y3RzJGWnJ2ay01TVFxbzl5SFVLaktPLUxwMlRLX2k2QmJ4N01YNU5rUFYzMktVMjYwNzAxem5JNGF6eFhQcDlYOGtzeU5pRExUMlpSNlJ5eS1aQ3dKTGJsREJIckthMnQtZ2ZV?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Corp (KTTA) Institutional Confidence", "summary": "This article provides an overview of Pasithea Therapeutics Corp (KTTA)'s institutional confidence, highlighting the institutional shareholding. It lists several key institutional investors and their respective shareholdings in the company. The data indicates that the institutiona", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ktta/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T17:40:27", "published_display": "18 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pasithea-therapeutics-amends-pas-004-123439880.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:34:39+00:00", "published_display": "16 Jun 2026 12:34", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pasithea-therapeutics-announces-amendments-clinical-110000209.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T11:00:00+00:00", "published_display": "16 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea NF1 trial to track patients for 18 months, expand PAS-004 dosing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNRE8xYm5mRHdnTFc0Vk5VMDVFS29Cd3FQdjl1eUFRaVkxYjFJemZ5Q0ZzZmxXTkZ3TXVEcE1acjBFOExqVXE3Y0tmS1lnRjNaSXgzZi1tdE1RX01acFJtSkJJLWdmOENua3R4VURRb09rcldhOG9iQlZIcmIyaS1JWWFvZEQzSnhuX1pjLU5JSVNmbGphTjlqcVBWbzRYdklNN2hlZThBeUZRTzA4d2JKWGlmOGkzQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Announces Exhibit at Children\u2019s Tumor Foundation 2026 NF Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pasithea-therapeutics-announces-exhibit-children-110200870.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T11:02:00+00:00", "published_display": "15 Jun 2026 11:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea brings NF1 drug PAS-004 to 2026 Denver NF conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNTS1UWDdINHBUSUlzWDg3d0xEYmRsTVptdGtpVFV3d2FkQzN4RWt5TTNTbnAxaWhQejNRRGZFYUxzYklScGM1OUp1YmNhVTE2R2o2UmVSdkNZenV0cHYtSUtweFdqUzMyaUcxRE1XLUxZbUc3bGZ3TUozdlBSRHVJYWtQdEdKS2RSajFRbWZRQ1BFVDYtZTBWREU2eDZRV3oySERYWjBqMFVkb1FLNEtpX29sTkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTmtuWV9objRLX1BxV09zNzN4M0xNQ0Z6aGRKczVUc29LelItRkhoQjdJeldlVWZ4NHJNQXZDN25iNG5LN3BBLWZqTU5XbjNfbVVRc0pvWTc2RVE4UXRDMktQVDRGZnF6TWgybXZLSzdWeEdrTC1yczl2MEJzQlQ1VUdqMXhCUnEzbHd2aGNtalZqRTYtRnpNTWZzVjBJUDY5ck9JY2stVTU?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Pasithea Therapeutics (KTTA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5PMTA3MEY3NzhXb2M2NWdVaDdCbjFZUTR3UW05S3RLeXFwYmliUk5CSTFYbEgzU0Q4WTNRYkozVFJSbUFuMkVoRF9vcWsyQkNqbE5RdHhONFJLVFFqd0lzMmxvQ2tUR3g1S1dySw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Gets US FDA Orphan Drug Status for ALS Candidate", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pasithea-therapeutics-gets-us-fda-112510189.html", "source_name": "MT Newswires", "published_at": "2026-06-02T11:25:10+00:00", "published_display": "02 Jun 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA grants rare-disease status to Pasithea ALS drug PAS-004", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQZFVCRGEyNnlpMjlXT1FwOGZxOG9IZVc2RG5mQTMyaVFhZ0VHVnVwZjZtMTdqUVh6UXdPRWNtNzdoMHFFaTUzaFNOcWc3a1BhZ0cwdzVPazZBZkNVZWs2eUY1MmdZX3gzbHE4TEtQWGhNSURTcTl1SmstNDBEWUZvNXRnbzdCR1huSGVoZDVud1U3Z0EyU0ZkSF8tMjYwemRZTW04U1NsQWxXTHU5TTlidVdrSkg1aUM0U0RhQg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pasithea names Kartik Krishnan as chief medical officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOaWZieVpFMEdLaGRLS0pwTE5YWUlZNVVQS3ZIRFZvY21ZVEEtUU5ac3Mtc3ZZendPZkZoc1JoM0l6QzRmMENRcWRxelJrNURXbXVmRjFac19FaW9QdGNSZDRnSWN4Y2REZHUycWNnSkN4Y21MU1BuM1Rob212WmFQWXVLUEd5NzFhU0REVFpMRnZCNmU3SF9GZjR1U0Q4N1RWQ0RZaVEtZlVxaTU4LWZzN2t3?oc=5", "source_name": "Investing.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNUnBkWkkzeVBxZHBrbVJXMUZmSk5kMUU4alRtd1dHem95OG5Belk2bUVNa0FlRDFHcEN6TlkwSl92THo2bi1Xem1iLVlxRXREajJUakswdTcxSFhNUTEyZ1FPckU5RXNxdzFBWmpvemplZWJuanhqa0gzalA4ajJjcDE0Q2NEakN2a09aUm1TdUtqeHVRSEltbzVwZWRqWGk4UWk3OFVXbFB4UUV1Y3hWcXo2RVRoRGdQa0VCS3ZxS3hhaExMdFkyc1lnUmtjWTZkRTJKcmZPRkpMSUJWTTI5MzQ4aHFrQ0FNSUNN0gHwAUFVX3lxTE9VdXIwUV9icGhndi1qYW9RZWVoZnlUeVFpRFZCUkFJSm9uOFhHMVlBWkFGNG5GQXJhSXBldkU3UHhDdlVFVUNwWmJjcUo2eHNvcWVWMDF3WmRaY0xvdHNuUGRkbE9WcVZKcEx3NENRSWlRT2FRNmFORVZMMW9XR2pjbEJSVkluVUJnaUNXSGZhZnpNOTJYS0Y2SjcyZnlqemxYYVMzZ1dFQmZuSGVUaXpuTU01bEpFUGllQ2NmQkVFbTdyWnQ0QTl6Tkg0V2NyaXhDSkNUSmdmdTdra0pWcDEzMnVCUkFlSHp4YWdyQWtRQw?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea\u2019s Stock Surge: Is It Time to Invest?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQUHkzMF9HWUl5cV9weERWR0s5SlRjdklWaHk4YWNxUF9EdWViSmFUTjN2a0JmZDJqWk9fOGQtZzBhOWxRUXNxeFF6cDB5OW1Oby1zaEI3Qi0yREJHVEFUZTVpeUdYR2JaTTFZZ2JCbE9hVnBldDNBQUg5UjBmMGNzSGp4Y2hMUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-11-28T08:00:00+00:00", "published_display": "28 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KTTA Stock Price and Chart \u2014 NASDAQ:KTTA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9ucnN2dWswZnQwd0RUZ25nRlVFNlRBUHplb0NtR2lqSWc0WTdER2Jya2Y1UjJPOFdqSldwbU5sMDdISm9hdE5YRjBzN2FGRDJ4UU1Xb2d1QVVfbWFr?oc=5", "source_name": "TradingView", "published_at": "2025-11-27T08:00:00+00:00", "published_display": "27 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxONFphZHExbHFKd1p2enQ3UmU1dlh3QURMMEQxNDI1UVFXSk82czV4Wjh6T1VEN2ZpYWduOXBOWWVrbFR2T2oyZ2swenZkU09lSFpYbjg5N3dGQTZIcEYtYjZaWVpBTGd2aFM3Sm1La1otaU9aZENIOTZRLUIyTGczM0JnWjFsZXJjamFaN0pBdWxNV0ExeHdmSWc3UzJJTEtFcnM0VHUzb1BQOFRYZzZNWUlFOTI?oc=5", "source_name": "Sahm", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Pasithea Therapeutics (KTTA) Proxy filing Summary", "summary": "Pasithea Therapeutics (KTTA) has released a summary of its proxy filing. The annual meeting, scheduled for September 3, 2025, will cover four key proposals including director elections, auditor ratification, an amendment to the 2023 Stock Incentive Plan, and a reverse stock split", "url": "https://quartr.com/events/pasithea-therapeutics-corp-ktta-proxy-filing_F15UA5TP", "source_name": "Quartr", "published_at": "2026-07-21T22:10:29", "published_display": "21 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics (KTTA) Registration filing Summary", "summary": "Pasithea Therapeutics (KTTA) is a clinical-stage biotechnology company focused on treatments for CNS disorders, RASopathies, MAPK pathway-driven tumors, and other diseases. The company reported net losses of $13.9 million in 2024 and $16.0 million in 2023, with an accumulated def", "url": "https://quartr.com/events/pasithea-therapeutics-corp-ktta-registration-filing_F15UA5Te", "source_name": "Quartr", "published_at": "2026-07-21T21:42:00", "published_display": "21 Jul 2026 21:42", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors", "summary": "Pasithea Therapeutics Corp. announced that its Phase 1 dose-escalation study for PAS-004, a macrocyclic MEK inhibitor, has been accepted for a poster presentation at the ESMO Congress 2026 on October 23. The study focuses on the safety and pharmacokinetics of PAS-004 in patients ", "url": "https://www.quiverquant.com/news/Pasithea+Therapeutics+Announces+ESMO+2026+Poster+Presentation+of+Phase+I+PAS-004+Study+in+Advanced+Solid+Tumors", "source_name": "Quiver Quantitative", "published_at": "2026-07-21T11:39:55", "published_display": "21 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea's PAS-004 Study of Advanced Solid Tumors Gets ESMO Poster Slot", "summary": "Pasithea Therapeutics (NASDAQ: KTTA) announced that its Phase I dose-escalation study data for PAS-004, a next-generation oral macrocyclic MEK inhibitor, in MAPK pathway-driven advanced solid tumors has been accepted for a poster presentation at the ESMO Congress 2026. The presen", "url": "https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-announces-presentation-of-pas-004-data-to-3m6zebfrchwt.html", "source_name": "Stock Titan", "published_at": "2026-07-21T10:39:54", "published_display": "21 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026", "summary": "Pasithea Therapeutics announced that data from its Phase 1 dose-escalation study of PAS-004, a macrocyclic MEK inhibitor, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. The presentation will detail the safety and pharmacokinetics of PAS-004 f", "url": "https://www.globenewswire.com/news-release/2026/07/21/3330295/0/en/pasithea-therapeutics-announces-presentation-of-pas-004-data-to-european-society-for-medical-oncology-esmo-congress-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-21T07:00:00", "published_display": "21 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit", "summary": "Pasithea Therapeutics Corp. announced its management will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston. The clinical-stage biotechnology company, focused on developing PAS-004 for chronic diseases and neurofibromatosis type 1, wi", "url": "https://www.sahmcapital.com/news/content/pasithea-therapeutics-announces-participation-in-b-riley-securities-mind-muscle-vision-summit-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-09T07:12:23", "published_display": "09 Jul 2026 07:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics to present at B. Riley Mi...", "summary": "Pasithea Therapeutics, a clinical-stage biotech company developing PAS-004 for chronic diseases like neurofibromatosis type 1, will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston. This summit offers an opportunity for Pasithea to e", "url": "https://pluang.com/en/news-feed/pasithea-therapeutics-ikuti-konferensi-b-riley-securities-mind-muscle-vision", "source_name": "Pluang", "published_at": "2026-07-08T11:10:56", "published_display": "08 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea management to meet investors at B. Riley health summit in Boston", "summary": "Pasithea Therapeutics (NASDAQ: KTTA) announced its management will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026, in Boston. The clinical-stage biotech, focusing on its lead drug candidate PAS-004 for chronic diseases including NF1, will eng", "url": "https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-announces-participation-in-b-riley-securities-2n9dyfpfv6y1.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:10:56", "published_display": "08 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings", "summary": "This page provides access to Pasithea Therapeutics Corp.'s financial disclosures and SEC filings, including quarterly and annual reports (10-Q and 10-K forms). Investors can use these documents to evaluate the company's financial performance and operational updates. The filings s", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTAW/documents/", "source_name": "TradingView", "published_at": "2026-07-02T00:40:00", "published_display": "02 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) \u2014 11.48% disclosed", "summary": "Coastlands Capital LP and its affiliated entities, along with Matthew D. Perry, have disclosed a beneficial ownership of 3,835,035 shares, representing an 11.48% stake in Pasithea Therapeutics (KTTA). This information comes from a Schedule 13G/A SEC filing, indicating a passive i", "url": "https://www.stocktitan.net/sec-filings/KTTA/schedule-13g-a-pasithea-therapeutics-corp-amended-passive-investment--0dbdebe49e63.html", "source_name": "Stock Titan", "published_at": "2026-07-02T00:40:00", "published_display": "02 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies.", "summary": "Pasithea Therapeutics Corp. has announced that its drug candidate, Pas-4, exhibited a favorable safety profile in clinical studies, with all observed adverse events being grade 1 or 2. This positive safety data is crucial for the drug's continued clinical development and potentia", "url": "https://www.bitget.com/amp/news/detail/12560605483584", "source_name": "Bitget", "published_at": "2026-06-30T15:09:58", "published_display": "30 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea reports positive PAS-004 Phase 1 cancer data", "summary": "Pasithea Therapeutics announced positive interim Phase 1 data for its oral MEK inhibitor, PAS-004, in patients with advanced MAPK pathway-driven solid tumors. The study revealed a favorable safety profile and instances of disease stabilization exceeding six months in heavily pret", "url": "https://grafa.com/en/news/united-states/pasithea-therapeutics-pas004-phase1-interim-results", "source_name": "grafa.com", "published_at": "2026-06-30T14:09:58", "published_display": "30 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Says Interim Phase 1 Data for PAS-004 Show Durable Clinical Activity", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pasithea-therapeutics-says-interim-phase-121951997.html", "source_name": "MT Newswires", "published_at": "2026-06-30T12:19:51+00:00", "published_display": "30 Jun 2026 12:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion", "summary": "Pasithea Therapeutics announced positive interim Phase 1 data for its drug candidate PAS-004 in advanced cancer patients, demonstrating favorable long-term safety and durable clinical activity, particularly in MEK/BRAF-pretreated individuals. The company noted that PAS-004 has be", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319538/0/en/pasithea-therapeutics-announces-positive-interim-phase-1-advanced-cancer-study-data-demonstrating-long-term-safety-and-tolerability-and-durable-clinical-activity-in-mek-braf-pretre.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T11:09:25", "published_display": "30 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens", "summary": "Pasithea Therapeutics announced positive interim Phase 1 data for PAS-004 in advanced cancer patients, showing favorable safety and durable disease stabilization. The oral MEK inhibitor demonstrated strong tolerability, with all adverse events being Grade 1\u20132, and pharmacokinetic", "url": "https://www.stocktitan.net/news/KTTA/pasithea-therapeutics-announces-positive-interim-phase-1-advanced-um0jjlpge3s6.html", "source_name": "Stock Titan", "published_at": "2026-06-30T11:09:25", "published_display": "30 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pasithea Therapeutics Corp. \u2013 NASDAQ:KTTA", "summary": "This article focuses on the enterprise value to revenue forward metric for Pasithea Therapeutics Corp. (NASDAQ: KTTA). It is a brief financial snippet from TradingView, highlighting a specific valuation ratio for the company. The content appears to be a stub or a section of a lar", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:41:04", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Pasithea Therapeutics Corp. \u2013 NASDAQ:KTTA", "summary": "This article displays the \"Price to book forward\" financial metric for Pasithea Therapeutics Corp. (NASDAQ: KTTA) on TradingView. It appears to be a stub or a data point within a larger financial platform, showing the value and changes for this specific financial indicator over a", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T06:42:48", "published_display": "29 Jun 2026 06:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pasithea Therapeutics Corp. \u2013 NASDAQ:KTTA", "summary": "This article provides a brief financial overview of Pasithea Therapeutics Corp. (NASDAQ: KTTA), focusing on its price-to-sales forward metric. It indicates that the market was closed at the time of publication and that there were no trades. The article is sourced from TradingView", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:10:21", "published_display": "28 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Pasithea Therapeutics Corp. \u2013 BOATS:KTTAW", "summary": "The article focuses on the \"Price to sales forward\" metric for Pasithea Therapeutics Corp. (KTTAW) on the Blue Ocean Alternative Trade System (BOATS). It notes that the market was closed and there were no trades recorded for this specific financial indicator. The content is prima", "url": "https://www.tradingview.com/symbols/BOATS-KTTAW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:09:25", "published_display": "27 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Pasithea Therapeutics Corp. \u2013 BOATS:KTTAW", "summary": "This article provides the enterprise value to revenue forward for Pasithea Therapeutics Corp. (KTTAW), as presented on TradingView. It notes that the market is closed with no trades. The content primarily shows navigation elements and disclaimers rather than financial data.", "url": "https://www.tradingview.com/symbols/BOATS-KTTAW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:10:33", "published_display": "26 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Corp. Actuals & Estimates (NASDAQ:KTTA)", "summary": "This article provides key financial data and analyst estimates for Pasithea Therapeutics Corp. (NASDAQ:KTTA). It covers current stock performance, historical highs and lows, future price forecasts from analysts, and upcoming earnings dates, alongside other company financials and ", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T16:10:33", "published_display": "26 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Corp. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of Pasithea Therapeutics Corp.'s SEC filings and other financial documents, including annual 10-K and quarterly 10-Q reports, dating back to 2021. It also lists corporate events such as conference participations. The information aims to ", "url": "https://www.tradingview.com/symbols/NASDAQ-KTTA/documents/", "source_name": "TradingView", "published_at": "2026-06-24T05:10:02", "published_display": "24 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13G Pasithea Therapeutics Corp. For: 23 June By Investing.com", "summary": "This article announces the filing of a Form 13G for Pasithea Therapeutics Corp. on June 23. It reminds readers that trading in financial instruments and cryptocurrencies involves significant risks and that data on Investing.com may not be real-time or accurate.", "url": "https://m.za.investing.com/news/stock-market-news/form-13g-pasithea-therapeutics-corp-for-23-june-93CH-4341004?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-24T03:10:02", "published_display": "24 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Pasithea Therapeutics Corp For: 22 June By Investing.com", "summary": "This article announces the filing of a Form 4 for Pasithea Therapeutics Corp on June 22nd, as reported by Investing.com. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a co", "url": "https://ng.investing.com/news/stock-market-news/form-4-pasithea-therapeutics-corp-for-22-june-93CH-2568205", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T15:40:15", "published_display": "22 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coastlands Capital LP acquires $53,000 of Pasithea stock By Investing.com", "summary": "Coastlands Capital LP, a significant shareholder in Pasithea Therapeutics Corp., recently acquired 100,000 shares of the company's common stock for $53,000 at $0.53 per share. This transaction increases their indirect holdings to 3,835,035 shares, occurring after the stock experi", "url": "https://ng.investing.com/news/stock-market-news/coastlands-capital-lp-acquires-53000-of-pasithea-stock-93CH-2568193", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T14:39:14", "published_display": "22 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Coastlands Capital LP acquires $53,000 of Pasithea stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZ1B2cG8yTjA1VDJaXzBtUmNYMjcydVE1eTdUNmFjZXZBYUtHU1NaM0xZbWt2SzVrLXVUX0pmWFA2Y3VWbHh6MC1CMEtYRVlOaS1zQkc4c0Y3RzJGWnJ2ay01TVFxbzl5SFVLaktPLUxwMlRLX2k2QmJ4N01YNU5rUFYzMktVMjYwNzAxem5JNGF6eFhQcDlYOGtzeU5pRExUMlpSNlJ5eS1aQ3dKTGJsREJIckthMnQtZ2ZV?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Corp (KTTA) Institutional Confidence", "summary": "This article provides an overview of Pasithea Therapeutics Corp (KTTA)'s institutional confidence, highlighting the institutional shareholding. It lists several key institutional investors and their respective shareholdings in the company. The data indicates that the institutiona", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ktta/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T17:40:27", "published_display": "18 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pasithea-therapeutics-amends-pas-004-123439880.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:34:39+00:00", "published_display": "16 Jun 2026 12:34", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/pasithea-therapeutics-announces-amendments-clinical-110000209.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T11:00:00+00:00", "published_display": "16 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea NF1 trial to track patients for 18 months, expand PAS-004 dosing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNRE8xYm5mRHdnTFc0Vk5VMDVFS29Cd3FQdjl1eUFRaVkxYjFJemZ5Q0ZzZmxXTkZ3TXVEcE1acjBFOExqVXE3Y0tmS1lnRjNaSXgzZi1tdE1RX01acFJtSkJJLWdmOENua3R4VURRb09rcldhOG9iQlZIcmIyaS1JWWFvZEQzSnhuX1pjLU5JSVNmbGphTjlqcVBWbzRYdklNN2hlZThBeUZRTzA4d2JKWGlmOGkzQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Announces Exhibit at Children\u2019s Tumor Foundation 2026 NF Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pasithea-therapeutics-announces-exhibit-children-110200870.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T11:02:00+00:00", "published_display": "15 Jun 2026 11:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea brings NF1 drug PAS-004 to 2026 Denver NF conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNTS1UWDdINHBUSUlzWDg3d0xEYmRsTVptdGtpVFV3d2FkQzN4RWt5TTNTbnAxaWhQejNRRGZFYUxzYklScGM1OUp1YmNhVTE2R2o2UmVSdkNZenV0cHYtSUtweFdqUzMyaUcxRE1XLUxZbUc3bGZ3TUozdlBSRHVJYWtQdEdKS2RSajFRbWZRQ1BFVDYtZTBWREU2eDZRV3oySERYWjBqMFVkb1FLNEtpX29sTkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTmtuWV9objRLX1BxV09zNzN4M0xNQ0Z6aGRKczVUc29LelItRkhoQjdJeldlVWZ4NHJNQXZDN25iNG5LN3BBLWZqTU5XbjNfbVVRc0pvWTc2RVE4UXRDMktQVDRGZnF6TWgybXZLSzdWeEdrTC1yczl2MEJzQlQ1VUdqMXhCUnEzbHd2aGNtalZqRTYtRnpNTWZzVjBJUDY5ck9JY2stVTU?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Pasithea Therapeutics (KTTA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5PMTA3MEY3NzhXb2M2NWdVaDdCbjFZUTR3UW05S3RLeXFwYmliUk5CSTFYbEgzU0Q4WTNRYkozVFJSbUFuMkVoRF9vcWsyQkNqbE5RdHhONFJLVFFqd0lzMmxvQ2tUR3g1S1dySw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea Therapeutics Gets US FDA Orphan Drug Status for ALS Candidate", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/pasithea-therapeutics-gets-us-fda-112510189.html", "source_name": "MT Newswires", "published_at": "2026-06-02T11:25:10+00:00", "published_display": "02 Jun 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA grants rare-disease status to Pasithea ALS drug PAS-004", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQZFVCRGEyNnlpMjlXT1FwOGZxOG9IZVc2RG5mQTMyaVFhZ0VHVnVwZjZtMTdqUVh6UXdPRWNtNzdoMHFFaTUzaFNOcWc3a1BhZ0cwdzVPazZBZkNVZWs2eUY1MmdZX3gzbHE4TEtQWGhNSURTcTl1SmstNDBEWUZvNXRnbzdCR1huSGVoZDVud1U3Z0EyU0ZkSF8tMjYwemRZTW04U1NsQWxXTHU5TTlidVdrSkg1aUM0U0RhQg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea names Kartik Krishnan as chief medical officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOaWZieVpFMEdLaGRLS0pwTE5YWUlZNVVQS3ZIRFZvY21ZVEEtUU5ac3Mtc3ZZendPZkZoc1JoM0l6QzRmMENRcWRxelJrNURXbXVmRjFac19FaW9QdGNSZDRnSWN4Y2REZHUycWNnSkN4Y21MU1BuM1Rob212WmFQWXVLUEd5NzFhU0REVFpMRnZCNmU3SF9GZjR1U0Q4N1RWQ0RZaVEtZlVxaTU4LWZzN2t3?oc=5", "source_name": "Investing.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pasithea\u2019s Stock Surge: Is It Time to Invest?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQUHkzMF9HWUl5cV9weERWR0s5SlRjdklWaHk4YWNxUF9EdWViSmFUTjN2a0JmZDJqWk9fOGQtZzBhOWxRUXNxeFF6cDB5OW1Oby1zaEI3Qi0yREJHVEFUZTVpeUdYR2JaTTFZZ2JCbE9hVnBldDNBQUg5UjBmMGNzSGp4Y2hMUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-11-28T08:00:00+00:00", "published_display": "28 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KTTA Stock Price and Chart \u2014 NASDAQ:KTTA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9ucnN2dWswZnQwd0RUZ25nRlVFNlRBUHplb0NtR2lqSWc0WTdER2Jya2Y1UjJPOFdqSldwbU5sMDdISm9hdE5YRjBzN2FGRDJ4UU1Xb2d1QVVfbWFr?oc=5", "source_name": "TradingView", "published_at": "2025-11-27T08:00:00+00:00", "published_display": "27 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxONFphZHExbHFKd1p2enQ3UmU1dlh3QURMMEQxNDI1UVFXSk82czV4Wjh6T1VEN2ZpYWduOXBOWWVrbFR2T2oyZ2swenZkU09lSFpYbjg5N3dGQTZIcEYtYjZaWVpBTGd2aFM3Sm1La1otaU9aZENIOTZRLUIyTGczM0JnWjFsZXJjamFaN0pBdWxNV0ExeHdmSWc3UzJJTEtFcnM0VHUzb1BQOFRYZzZNWUlFOTI?oc=5", "source_name": "Sahm", "published_at": "2025-11-26T08:00:00+00:00", "published_display": "26 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 51, "sentiment_summary": {"positive": 17, "negative": 3, "neutral": 31, "score": 56, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 87, "events": [{"event": "general", "label": "Market update", "weight": 21.25, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 0.45, "latest_week": "2026-07-17", "one_week_move": -8.6, "four_week_move": -10.0, "twelve_week_move": -34.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.966621, "market_dynamics_buy_signal": false, "relative_strength": -48.339358, "fair_value_gap": -87.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 41.6467, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.6% over one week, -10.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Stock Titan", "count": 7}, {"label": "Market source", "count": 7}, {"label": "GlobeNewswire", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "Sahm", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "87/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-8.6% over one week, -10.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Pasithea Therapeutics (KTTA) Proxy filing Summary"}], "updated_at": "2026-07-23T07:13:14.427430+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}